Metropolis Healthcare Ltd

BSE
METROPOLIS •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or open an account for live prices.
Start SIP in Metropolis Healthcare Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W High in past week
16.2
TTM PE Ratio
High in industry
81.3
Price to Book Ratio
High in industry
9.5
Dividend yield 1yr %
Low in industry
0.2
TTM PEG Ratio
PEG TTM is negative
-7.7
RSI
RSI is mid-range
56.4
MFI
MFI Overbought
72

Metropolis Healthcare Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Metropolis Healthcare Ltd shareholding Pattern

Promoter
49.7%
Foreign Institutions
18.9%
Mutual Funds
21.3%
Domestic Institutions
24.9%
Public
6.6%
Promoter
49.7%
Foreign Institutions
21.7%
Mutual Funds
16%
Domestic Institutions
20.7%
Public
7.9%
Promoter
49.7%
Foreign Institutions
24.3%
Mutual Funds
14%
Domestic Institutions
16.9%
Public
9.1%
Promoter
49.8%
Foreign Institutions
25.7%
Mutual Funds
13.3%
Domestic Institutions
14.9%
Public
9.7%
Promoter
49.8%
Foreign Institutions
25.7%
Mutual Funds
12.4%
Domestic Institutions
13.6%
Public
10.9%
Promoter
49.8%
Foreign Institutions
23.9%
Mutual Funds
11.8%
Domestic Institutions
13.3%
Public
13.1%

Metropolis Healthcare Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
11
Bearish Moving Averages
5
5Day EMA
2,052.40
10Day EMA
2,043.20
12Day EMA
2,038.40
20Day EMA
2,019.30
26Day EMA
2,005.40
50Day EMA
1,951.70
100Day EMA
1,862.00
200Day EMA
1,747.40
5Day SMA
2,055.90
10Day SMA
2,051.80
20Day SMA
2,007.60
30Day SMA
1,997.20
50Day SMA
1,949.10
100Day SMA
1,829.90
150Day SMA
1,769.20
200Day SMA
1,712.40
Delivery & Volume
Resistance & Support
2,048.63
Pivot
Resistance
First Resistance
2,073.72
Second Resistance
2,107.03
Third Resistance
2,132.12
Support
First Support
2,015.32
Second support
1,990.23
Third Support
1,956.92
Relative Strength Index
56.45
Money Flow Index
72
MACD
33.03
MACD Signal
32.87
Average True Range
57.53
Average Directional Index
19.33
Rate of Change (21)
4.20
Rate of Change (125)
35.68
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Kovai Medical Center and Hospital Ltd.
-
-
-
Dr. Lal Pathlabs Ltd.
25014.05
1943.2
3054.1
Thyrocare Technologies Ltd.
3401.15
511
722
Vijaya Diagnostic Centre Ltd.
7943.61
437.9
879.3
Medi Assist Healthcare Services Ltd.
3805.46
430.15
605.15
Entero Healthcare Solutions Ltd.
4976.56
974.45
1258

Metropolis Healthcare Ltd Company background

Founded in: 2000
Managing director: Ameera Sushil Shah
Dr. Sushil Kanubhai Shah, one of the Promoters, commenced pathology business in January 1980 as a partnership firm in the name of Dr. V. K. Desais Hospital, having Dr. Kanubhai M. Shah, Dr. Sushil Kanubhai Shah and Dr. Vasant Kalyandas Desai as partners. The partnership was continued by Dr. Sushil Kanubhai Shah, Dr. Kanubhai M. Shah and Dr. Duru Sushil Shah from September 30, 1981 onwards. In June 1989, upon death of Dr. Kanubhai M. Shah, the partnership was continued by Dr. Sushil Kanubhai Shah and Dr. Duru Sushil Shah. Prior to March 18, 1995, Dr. Sushil Kanubhai Shah was also carrying on a business of radioimmunoassay and pathology laboratory on a sole proprietorship basis. On March 20, 1995, the said sole proprietorship business was converted into a partnership with Dr. Sushil Kanubhai Shah, Dr. Duru Sushil Shah and Aparna S. Shah (Rajadhyaksha) as partners, in the name and style of Metropolis Lab. In January 1998, Ameera Sushil Shah was inducted as an additional partner in Metropolis Lab. With effect from February 1, 2002, the business of Metropolis Lab was transferred to Dr. V. K. Desais Hospital as a going concern. In May 2002, Dr. G. S. K. Velu and Subbulakshmi K. Velu were admitted as partners in Dr. V. K. Desai Hospitals. The name of Dr. V. K. Desais Hospital was changed to Metropolis Health Services in November 2002. Further, in April 2003, Ameera Sushil Shah, Jaswanti Kanubhai Shah, Sadacharan Gomanthybabu and Gomathybabu Gomathy were admitted as partners in Metropolis Health Services. In July 2003, Metropolis Health Services was converted into a private limited company as Metropolis Health Services (India) Private Limited (MHSIPL). The name of MHSIPL was changed to Metropolis Health Services (India) Limited (MHSIL) pursuant to a Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company on March 1, 2006. In January 2009, MHSIL amalgamated with Pathnet India Private Limited, which was a wholly owned subsidiary of MHSIL. Metropolis Healthcare Ltd (Formerly known as Pathnet India Private Limited) was incorporated at New Delhi on November 10, 2000. The Company is one of the leading diagnostics companies in India. It has widespread presence across 220 cities in India with leadership position in West and South India. Through its widespread operational network, it offers a comprehensive range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. It also offers analytical and support services to clinical research organizations for their clinical research projects. Presently, it is engaged in the business of providing pathology and related healthcare services.The Company conducts its operations through their laboratory and service network. It has implemented a hub and spoke model for quick and efficient delivery of services through their widespread laboratory and service network, which covers 197 cities in India. As of December 31, 2018, its laboratory network consists of 115 clinical laboratories, comprising (i) a global reference laboratory (GRL) located in Mumbai, which is the main hub and equipped to conduct majority of the tests offered by them (ii) 14 regional reference laboratories (RRLs) (out of which four are located outside India), which are equipped to conduct routine, semispecialized and few specialized tests (iii) 56 satellite laboratories (out of which one is located outside India), which are equipped to conduct routine and semispecialized tests and (iv) 44 express laboratories (out of which five are located outside India), which are equipped to conduct routine tests. Metropolis Healthcare has been awarded the tender by the National Aids Control Organization (NACO) to collect specimens from 525 governmentowned antiretroviral therapy (ART) centers and conduct HIV1Viral load tests. It also offers analytical services and support services such as logistics and electronic data interchange (EDI) to contract research organizations for their clinical research projects. Outside India, it has laboratory operations in Ghana, Kenya, Zambia, Mauritius and Sri Lanka. In addition, it has also entered into agreements with third parties for collection and processing of specimens in Nepal, Nigeria, UAE and Oman. Metropolis brand is recognized for delivering quality diagnostic and related healthcare tests and services. For instance, it received excellence in customer service and delivery award from Biotrains in 2018, and also received special jury mention for service excellence (diagnostic center) by FICCI at the Healthcare Excellence Awards 2018. In addition, its health campaign was recognized as best in health and fitness in the Digital Campaign Awards 2018 by LH Insights.Metropolis Healthcare Ltd. came out with an Initial Public Offering (IPO) of 13,685,095 equity shares of Face Value of Rs 2/ each of the company for cash at a price of Rs 880 per equity share aggregating Rs 1204.29 Crores, consisting of an offer for sale of 6,272,335 equity shares by Dr. Sushil Kanubhai Shah (the promoter selling shareholder) aggregating to 551.97 Crores and 7,412,760 equity shares by Ca Lotus Investments (the investor selling shareholder) aggregating 652.32 Crores. The face value of equity shares is Rs 2/each. The IPO was priced at Rs 880 per equity share.During the year 201819, the Wholly Owned Subsidiaries viz., Bacchus Hospitality Services and Real Estate Private Limited Metropolis Healthcare (Chandigarh) Private Limited, Metropolis Healthcare (Jodhpur) Private Limited, Sanket Metropolis Health Services (India) Private Limited, Final Diagnosis Private Limited and Golwilkar Metropolis Health Services (India) Private Limited amalgamated with the Company (Transferee Company) effective from 08 September 2018. Further, the Transferee Company on 08 September 2018 allotted 26,57,731 fully paid up Equity Shares of Rs 10/ each in the ratio of 957,713 Equity Shares of Rs 10/ each to the shareholders of Bacchus for every 10,00,000 Equity Shares of Rs 10/ each held in Bacchus (Prebonus and Subdivision). The wellness initiative TruHealth was launched across 36cities in FY19 launched Medengage, to nurture upcoming medical talent. A wide range of 3,487 clinical laboratory tests and 530 profiles were offered by Metropolis as of March 2019. The equity shares of Company were listed on BSE Ltd and the National Stock Exchange of India Limited with effect from April 15, 2019.The Company acquired four frontend labs in Surat in FY 2020. It acquired 51% of stake i.e. 5,100 Equity Shares of Shraddha Diagnostic Centre (I) Private Limited (SDCIPL) from the existing shareholders at a consideration of Rs 9,36,30,000/. It further acquired a total of 550 equity shares of the Target Company (constituting 5.5 % of its Share Capital) on April 7, 2020 for a consideration of Rs 1 Crores.During the year 202021, the Company acquired the balance stake of 49% in Raj Metropolis and with effect from November 5, 2020 and as a result, Raj Metropolis became a whollyowned subsidiary of the Company. In the financial year 202122, Metropolis strengthened its operations by adding 16 labs and 506 network centres, as a part of expansion plan of adding 90 labs and 1,800 network centres by FY 24. It acquired the 100% stake in Dr. Ganesans Hitech Diagnostics Centre Private Limited along with its subsidiary Centralab Healthcare Services Private Limited and post completion of acquisition, Hitech and Centralab became whollyowned subsidiary and step down wholly owned subsidiary respectively of Company effective 22 Oct 2021. Similarly, during the year 202122, Company had acquired balance stake of 35% of Metropolis Histoexpert Digital Services Private Limited, Subsidiary of the Company from Koninklijke Philips N.V. Post the acquisition, Metropolis Histoxpert became the whollyownedSubsidiary of the Company with effect from 26 November 2021.During the year 202223, the Company launched some complex tests using Next Generation Sequencing (NGS) Technology for Prenatal screening, Breast Cancer, Bone Marrow Transplant and Allergy Component Testing powered by Artificial Intelligence. In FY 23, it added 14 labs and approximately 548 centers during the year, built a new management team to run the business, integrated the technology offering with Metropolis and executed some cost synergies further added 83 new tests. During year 202223, the subsidiary companies, M/s. Bokil Golwilkar Metropolis Healthcare Private Limited, M/s. Desai Metropolis Health Services Private Limited, M/s. Dr. Patel Metropolis Healthcare Private Limited, M/s. Lab One Metropolis Healthcare Services Private Limited, M/s. Micron Metropolis Healthcare Private Limited, M/s. R. V. Metropolis Diagnostic Health Care Center Private Limited, M/s. Raj Metropolis Healthcare Private Limited and M/s. Sudharma Metropolis Health Services Private got merged with the Company through the Scheme of Amalgamation, which was made effective from July 11, 2022.
Read More

Metropolis Healthcare Ltd FAQs

The past 1-year return of Metropolis Healthcare Ltd [METROPOLIS] share was 40.21. The Metropolis Healthcare Ltd [METROPOLIS] share hit a 1-year low of Rs. 1296 and a 1-year high of Rs. 2120.9.

The Mutual Fund Shareholding was 21.31% at the end of .

You can easily buy Metropolis Healthcare Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -